- > Media & Investors
- > Media Relations
- > Press Releases
- > Daiichi Sankyo Announces Installation of Onsite Solar Power System at Onahama Plant in Japan
For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Sunao Manabe, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Junichi Onuma,
Vice President, Corporate Communications Department
Daiichi Sankyo Announces Installation of Onsite Solar Power System at Onahama Plant in Japan
Tokyo, Japan (October 8, 2019) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has decided to install an onsite solar power system at its Onahama Plant in Iwaki City, Fukushima Prefecture, Japan.
The solar power generation facility is expected to generate 3.3 megawatts of power (annual power output: 4,155 MWh) for use at the plant and would be one of the largest onsite systems in Japan in the pharmaceutical industry. It is planned to be completed and go into operation in fiscal 2020.
By making use of reusable energy produced by sunlight, Daiichi Sankyo expects an approximately 1,800 ton/year reduction in CO2 emissions. This is equivalent to approximately 20% of the total annual volume of CO2 produced by the plant.
NTT Facilities, Inc. will build, own and maintain the onsite solar power system for the plant.
Grounded in our “Overview and Progress of 5-year Business Plan: Environmental Management Policy,” Daiichi Sankyo set as our long-term goal based on scientific evidence to be achieved by 2030 as “a 27% reduction in total volume of CO2 emissions*1 as compared to fiscal 2015.” Daiichi Sankyo received the second approval among Japanese companies from Science Based Targets initiatives*2 as a goal consistent with scientific evidence in September 2016.
The Daiichi Sankyo group will work toward achieving a low-carbon society in local communities and protecting the environment while also proactively working to reduce CO2 emissions in all of its corporate activities.
*1 : Total volume of CO2 emitted directly from Daiichi Sankyo plants and offices combined with the CO2 emitted indirectly from the use of energy(mainly electric power) supplied from outside the Daiichi Sankyo group.
*2 : An international initiative that encourages companies to set CO2 reduction targets based on scientific evidence in order to help accomplish the goal of the Paris Agreement of keeping the average increase in global temperature below 2º C.
Concept drawing of the Onahama Plant onsite solar power system following completion
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.